Abbvie Inc (ABBV)

$227.99 -0.26 (-0.11%)
Market Cap 403.22B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 21.59
Forward PE 21.29
Profit Margin 7.59%
Debt to Equity Ratio -510.73
Volume 3,554,600
Avg Vol 5,504,924
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 36%
Beta 0.51
Analysts Strong Sell
Price Target $239.72

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
dogDazeSummer
dogDazeSummer Oct. 25 at 9:00 PM
$IFRX “Biogen’s move sets a valuation benchmark and elevates IFRX’s strategic relevance. From a market-impact standpoint, Biogen’s entry effectively establishes a valuation benchmark for oral C5aR1 inhibitors and strengthens the strategic optionality for IFRX. Should INF904’s P2 data demonstrate strong efficacy and tolerability, InflaRx could be viewed as a de-risked, clinically advanced complement play which would suggest an attractive acquisition or partnering candidate for companies seeking nearer-term exposure to the C5aR class. Net-net, this $BIIB transaction serves as both mechanistic validation and sentiment catalyst ahead of IFRX’s upcoming readout, sharpening investor focus on INF904 as a leading near-term asset in the emerging oral complement inhibitor space.” $XBI $RHHBY $ABBV
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 6:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABBV Current Share Price: $227.99 Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $23.18- $28.33 Scale out: $36.05-$46.35 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 25 at 4:50 PM
$BIIB $AMGN $ABBV If they are “biosimilar” - the market needs to re- price $IFRX Grok: How does Vanqua C5aR VQ-201 differ from Inflarx INF904 and cld they be used for same indications? VQ-201 (Vanqua Bio/Biogen) vs. INF904 (InflaRx) Both are oral, allosteric C5aR1 antagonists blocking complement-driven neutrophil inflammation more selectively than first-gen drugs like avacopan (which has hepatotoxicity risks). They bind to active site for better safety. Mechanism: VQ-201 inhibits leukocyte chemotaxis/activation without first-gen liabilities. INF904 binds in the lipid bilayer, offering high affinity, minimal CYP interactions, and superior exposure (3x higher C_max, 10x AUC vs. avacopan). - Caveats: INF904's Phase 2 data could validate the class quickest; VQ-201's may shine in long-term use. Tissue-specific PK could differentiate, but biology favors interchangeability. Overall, either could pivot to the other's niches with minimal tweaks watch INF904 topline catalysts.
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 25 at 12:28 AM
@FlowerInTheCellar @MrCompassion I also like that RA has sold 4 companies to $ABBV in last 12 months. It’s sooooo clear that Peter has a direct line to CEO of Abbie. Now that both $AMGN $BIIB have their own C5aR inhibitors —-How can $RHHBY and $ABBV wander around naked & unable to battle inflammation without a black box? AAV, ARDS, Alzheimer’s, Dementia, Renal, Cancers (lung, thyroid, pancreatic), Dermatological, cardiac—-PG, HS, CSU- any 1 is $1B+ After biogen dropped up to $1B+ today for the c5ra axis, I officially drank the cool aid and align with Mr Compassions thesis. Why invest up to $1B for a drug thats years behind INF904? B/c it’s prolly worth $10B long term revenue. B/c INF904 is prolly worth $3B-5b today. Yes. Today. Won’t be surprised to see weekend news stories and open at $2-$3- still 1/4 of what Biogen committed to. We’re just getting started in this ….all time high $50
0 · Reply
Emir_Hebert_89
Emir_Hebert_89 Oct. 24 at 6:36 PM
$ABBV flat 💉 dividend crowd steady, volume light
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 24 at 4:48 PM
$IFRX IMO this should be $2-$3 today based on $1B overall potential value $BIIB just ascribed. $AMGN is already in game with avacopan. $ABBV $RHHBY not yet. Someone please repost Tom comments (our CFO) when asked about funding INF904 P2b trials at Cantor conference. Part 2: “INF904’s clinical progress positions IFRX ahead of announced collaboration. Mechanistically, both Biogen’s and InflaRx’s programs aim to attenuate the same receptor axis (C5aR1), which mediates neutrophil recruitment and activation downstream of complement component C5a. While Vanqua Bio’s molecule remains pre-IND, INF904 is already in phase 2 with POC data expected imminently. Recall, INF904 has shown optimized profile in phase 1 including no DLTs, superior systemic exposure, durable target coverage, cleaner drug-drug interaction profile, and consistent >90% ex vivo inhibition of C5a activity positions.”
2 · Reply
cb5000calls
cb5000calls Oct. 24 at 2:36 PM
$SLS This is a cornerstone IP filing — not a generic chemistry patent but a precision-medicine lock around ASXL1-mutated cancers. It secures Sellas’ differentiation in AML and MDS and supports expansion into solid tumors (colorectal, liver, breast). The inclusion of venetoclax + azacitidine combinations directly positions this as first-line-compatible with current AML standards. Expect this to be a core due-diligence element if any large pharma (e.g., $ABBV , $BMY , $PFE ) considers acquisition or co-development. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025217597
2 · Reply
Luckyjs38
Luckyjs38 Oct. 24 at 2:35 PM
$ABBV their Business model is to steal intellectual properties that are patented by other companies and reap the benefits. 🤬 pay us what is rightfully ours stealing from another company and their share holder value is evil $ENVB
0 · Reply
Lavishstock
Lavishstock Oct. 24 at 4:46 AM
$ABBV
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 4:19 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABBV Current Share Price: $229.17 Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $23.98- $29.32 Scale out: $37.31-$47.97 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Latest News on ABBV
Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks

Oct 21, 2025, 2:27 PM EDT - 4 days ago

Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks

APTV PANW QCOM

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

Oct 21, 2025, 8:00 AM EDT - 4 days ago

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

AbbVie's Rinvoq shows superiority over Humira in head-to-head study

Oct 20, 2025, 8:12 AM EDT - 5 days ago

AbbVie's Rinvoq shows superiority over Humira in head-to-head study

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

Oct 20, 2025, 8:00 AM EDT - 5 days ago

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

Oct 17, 2025, 4:34 PM EDT - 8 days ago

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Oct 17, 2025, 9:00 AM EDT - 8 days ago

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

Oct 13, 2025, 1:28 PM EDT - 12 days ago

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

AMZN DDOG TSLX

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

Oct 13, 2025, 10:57 AM EDT - 12 days ago

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Oct 13, 2025, 7:15 AM EDT - 12 days ago

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

Oct 9, 2025, 8:00 AM EDT - 16 days ago

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 19 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ALVO AMGN ARKG AZN BIIB BMY GILD

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

Oct 6, 2025, 9:00 AM EDT - 19 days ago

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

AbbVie expects $2.7 billion R&D charge in third quarter

Oct 3, 2025, 4:16 PM EDT - 22 days ago

AbbVie expects $2.7 billion R&D charge in third quarter

AbbVie: Wins Accumulating While We Wait For Next BD Steps

Oct 3, 2025, 11:05 AM EDT - 22 days ago

AbbVie: Wins Accumulating While We Wait For Next BD Steps

ABBV Stock vs. Eli Lilly & Merck

Oct 2, 2025, 8:20 AM EDT - 23 days ago

ABBV Stock vs. Eli Lilly & Merck

LLY MRK

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Oct 2, 2025, 8:00 AM EDT - 23 days ago

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Natrelle® Awarded Supplier Agreement from Vizient

Oct 1, 2025, 8:00 AM EDT - 24 days ago

Natrelle® Awarded Supplier Agreement from Vizient

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

Sep 30, 2025, 3:00 PM EDT - 25 days ago

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

Sep 30, 2025, 8:00 AM EDT - 25 days ago

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Sep 29, 2025, 7:30 PM EDT - 25 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

Sep 29, 2025, 12:00 PM EDT - 26 days ago

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

AbbVie to launch ovarian cancer drug in UK at the same list price as US

Sep 29, 2025, 9:11 AM EDT - 26 days ago

AbbVie to launch ovarian cancer drug in UK at the same list price as US

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

Sep 29, 2025, 9:00 AM EDT - 26 days ago

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

AbbVie For Healthy Dividend Growth

Sep 27, 2025, 7:00 AM EDT - 4 weeks ago

AbbVie For Healthy Dividend Growth

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

Sep 26, 2025, 4:50 PM EDT - 4 weeks ago

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

AMGN LLY MRK

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

Sep 26, 2025, 1:47 PM EDT - 4 weeks ago

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

AMGN GILD LLY MRK MRNA PFE

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

Sep 26, 2025, 12:21 PM EDT - 4 weeks ago

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

LLY MRK PFE BIIB BMY

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

Sep 26, 2025, 8:45 AM EDT - 4 weeks ago

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists

Sep 25, 2025, 11:53 AM EDT - 4 weeks ago

AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists

Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai

Sep 25, 2025, 5:00 AM EDT - 4 weeks ago

Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai

These Dividend Stocks Have Big Yields and Are Beating the Odds

Sep 23, 2025, 2:47 PM EDT - 4 weeks ago

These Dividend Stocks Have Big Yields and Are Beating the Odds

ABT DGRO SDY VIG

Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality

Sep 23, 2025, 5:00 AM EDT - 4 weeks ago

Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality

These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech

Sep 22, 2025, 3:37 PM EDT - 4 weeks ago

These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech

AAPL AMZN AVGO COST GOOG GOOGL HD

Calls of the Day: Netflix, Disney, Walmart and AbbVie

Sep 17, 2025, 1:48 PM EDT - 5 weeks ago

Calls of the Day: Netflix, Disney, Walmart and AbbVie

DIS NFLX WMT

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Sep 17, 2025, 7:52 AM EDT - 5 weeks ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

MDT PINC

AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.

Sep 12, 2025, 9:57 AM EDT - 6 weeks ago

AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.

AbbVie shares hit record high as key immunology drug set for exclusivity until 2037

Sep 11, 2025, 12:25 PM EDT - 6 weeks ago

AbbVie shares hit record high as key immunology drug set for exclusivity until 2037

AbbVie in Settlement With Generic Drugmakers on Rinvoq

Sep 11, 2025, 12:17 PM EDT - 6 weeks ago

AbbVie in Settlement With Generic Drugmakers on Rinvoq

Why Is AbbVie Stock Trading Higher On Thursday?

Sep 11, 2025, 9:55 AM EDT - 6 weeks ago

Why Is AbbVie Stock Trading Higher On Thursday?

AbbVie: What's Happening With ABBV Stock?

Sep 11, 2025, 9:45 AM EDT - 6 weeks ago

AbbVie: What's Happening With ABBV Stock?

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

Sep 10, 2025, 1:03 PM EDT - 6 weeks ago

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

AZN GSK NVO NVS SNY AMGN LLY

AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 1:46 PM EDT - 6 weeks ago

AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

Sep 9, 2025, 8:00 AM EDT - 6 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 6 weeks ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

VEEV VRTX VST

AbbVie Declares Quarterly Dividend

Sep 5, 2025, 9:07 AM EDT - 7 weeks ago

AbbVie Declares Quarterly Dividend

Global drugmakers rush to boost US presence as tariff threat looms

Sep 3, 2025, 2:09 PM EDT - 7 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD JNJ LLY MRK

AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sep 3, 2025, 8:30 AM EDT - 7 weeks ago

AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

How To Invest $100,000 In A Near-Perfect Strategy Portfolio

Aug 30, 2025, 8:05 AM EDT - 2 months ago

How To Invest $100,000 In A Near-Perfect Strategy Portfolio

ADX BME CVX EOS FDVV HD JEPQ

AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin

Aug 29, 2025, 12:37 PM EDT - 2 months ago

AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin

dogDazeSummer
dogDazeSummer Oct. 25 at 9:00 PM
$IFRX “Biogen’s move sets a valuation benchmark and elevates IFRX’s strategic relevance. From a market-impact standpoint, Biogen’s entry effectively establishes a valuation benchmark for oral C5aR1 inhibitors and strengthens the strategic optionality for IFRX. Should INF904’s P2 data demonstrate strong efficacy and tolerability, InflaRx could be viewed as a de-risked, clinically advanced complement play which would suggest an attractive acquisition or partnering candidate for companies seeking nearer-term exposure to the C5aR class. Net-net, this $BIIB transaction serves as both mechanistic validation and sentiment catalyst ahead of IFRX’s upcoming readout, sharpening investor focus on INF904 as a leading near-term asset in the emerging oral complement inhibitor space.” $XBI $RHHBY $ABBV
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 6:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABBV Current Share Price: $227.99 Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $23.18- $28.33 Scale out: $36.05-$46.35 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 25 at 4:50 PM
$BIIB $AMGN $ABBV If they are “biosimilar” - the market needs to re- price $IFRX Grok: How does Vanqua C5aR VQ-201 differ from Inflarx INF904 and cld they be used for same indications? VQ-201 (Vanqua Bio/Biogen) vs. INF904 (InflaRx) Both are oral, allosteric C5aR1 antagonists blocking complement-driven neutrophil inflammation more selectively than first-gen drugs like avacopan (which has hepatotoxicity risks). They bind to active site for better safety. Mechanism: VQ-201 inhibits leukocyte chemotaxis/activation without first-gen liabilities. INF904 binds in the lipid bilayer, offering high affinity, minimal CYP interactions, and superior exposure (3x higher C_max, 10x AUC vs. avacopan). - Caveats: INF904's Phase 2 data could validate the class quickest; VQ-201's may shine in long-term use. Tissue-specific PK could differentiate, but biology favors interchangeability. Overall, either could pivot to the other's niches with minimal tweaks watch INF904 topline catalysts.
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 25 at 12:28 AM
@FlowerInTheCellar @MrCompassion I also like that RA has sold 4 companies to $ABBV in last 12 months. It’s sooooo clear that Peter has a direct line to CEO of Abbie. Now that both $AMGN $BIIB have their own C5aR inhibitors —-How can $RHHBY and $ABBV wander around naked & unable to battle inflammation without a black box? AAV, ARDS, Alzheimer’s, Dementia, Renal, Cancers (lung, thyroid, pancreatic), Dermatological, cardiac—-PG, HS, CSU- any 1 is $1B+ After biogen dropped up to $1B+ today for the c5ra axis, I officially drank the cool aid and align with Mr Compassions thesis. Why invest up to $1B for a drug thats years behind INF904? B/c it’s prolly worth $10B long term revenue. B/c INF904 is prolly worth $3B-5b today. Yes. Today. Won’t be surprised to see weekend news stories and open at $2-$3- still 1/4 of what Biogen committed to. We’re just getting started in this ….all time high $50
0 · Reply
Emir_Hebert_89
Emir_Hebert_89 Oct. 24 at 6:36 PM
$ABBV flat 💉 dividend crowd steady, volume light
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 24 at 4:48 PM
$IFRX IMO this should be $2-$3 today based on $1B overall potential value $BIIB just ascribed. $AMGN is already in game with avacopan. $ABBV $RHHBY not yet. Someone please repost Tom comments (our CFO) when asked about funding INF904 P2b trials at Cantor conference. Part 2: “INF904’s clinical progress positions IFRX ahead of announced collaboration. Mechanistically, both Biogen’s and InflaRx’s programs aim to attenuate the same receptor axis (C5aR1), which mediates neutrophil recruitment and activation downstream of complement component C5a. While Vanqua Bio’s molecule remains pre-IND, INF904 is already in phase 2 with POC data expected imminently. Recall, INF904 has shown optimized profile in phase 1 including no DLTs, superior systemic exposure, durable target coverage, cleaner drug-drug interaction profile, and consistent >90% ex vivo inhibition of C5a activity positions.”
2 · Reply
cb5000calls
cb5000calls Oct. 24 at 2:36 PM
$SLS This is a cornerstone IP filing — not a generic chemistry patent but a precision-medicine lock around ASXL1-mutated cancers. It secures Sellas’ differentiation in AML and MDS and supports expansion into solid tumors (colorectal, liver, breast). The inclusion of venetoclax + azacitidine combinations directly positions this as first-line-compatible with current AML standards. Expect this to be a core due-diligence element if any large pharma (e.g., $ABBV , $BMY , $PFE ) considers acquisition or co-development. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025217597
2 · Reply
Luckyjs38
Luckyjs38 Oct. 24 at 2:35 PM
$ABBV their Business model is to steal intellectual properties that are patented by other companies and reap the benefits. 🤬 pay us what is rightfully ours stealing from another company and their share holder value is evil $ENVB
0 · Reply
Lavishstock
Lavishstock Oct. 24 at 4:46 AM
$ABBV
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 4:19 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABBV Current Share Price: $229.17 Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $23.98- $29.32 Scale out: $37.31-$47.97 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Lavishstock
Lavishstock Oct. 24 at 4:16 AM
Bullish on $ABBV – steady dividends and strong pharma pipeline make this stock attractive. Check out this AI browser: https://pplx.ai/maxmasoodi63049
0 · Reply
Masonato
Masonato Oct. 24 at 12:52 AM
$ABBV
0 · Reply
scott52
scott52 Oct. 23 at 8:04 PM
$ABBV I'd love to see ABBV buy VKTX. There's huge upside potential there. With ABBV's expertise, I'll bet they can take at least 10% market share, that's $35B in revenue per year.
1 · Reply
Masonato
Masonato Oct. 23 at 6:41 PM
$ABBV https://finviz.com/news/202564/3-pharmaceutical-growth-stocks-to-buy-and-hold-for-10-years
0 · Reply
biolover
biolover Oct. 23 at 6:31 PM
$PFE $VKTX Just watch $LLY climbing up every day and Pfizer happy with MC of the Gilead level … good job Bourla and your obesity experts. remember party 2 ( likely $ABBV ) backed off after reviewing metsera data.
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 23 at 5:54 PM
$SLS $ABBV $SLS All the Board FUD is a BUY SIGN. Black Rock buying 5.4% starter Position Last week will be buying 100K Blocks at $50 - once the P3 Results are announced. The short Manipulation has contributed to offering all of us an Investment Opportunity of a Lifetime.
0 · Reply
LionsFan777
LionsFan777 Oct. 23 at 5:06 PM
$ABBV Looks like we are range bound until earnings. I'm bullish for $240.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 23 at 4:55 PM
$SLS This is the Math: dNPV 1,000 Institutional Fund Managers will be running NEXT week when they Realize Gps Immunotherapy is Getting FDA APPROVAL to treat 25,000 AML REMISSION PATIENTS. PSA: $ABBV/ $PFE or $MRK will be Paying a Premium to Include the AML CR1 Market - AZA+ VEN VIALE-M Just FAILED a 500 patient AML CR1 Phase 3 Maintenance Trial. AZA+VEN is the BAT for the SLS P3 Control ARM Patients AZA+VEN FAILED 3, Phase 3 AML Trials in the last few months - its toxic for the SLS P3 patients as well.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 23 at 3:43 PM
$SLS All the Short Lowlife Begging for Sellers, pleading with us to Not BUY MORE -- are buy signs. Aza+ VEN, BAT - Best Available Treatment for the SLS REGAL P3 Control Arm Patients FAILED 3 Phase 3 AML Trials in the last couple of Months. 3 Large Expense Phase 3's Viale-M Viale-T Verona Again - Aza + VEN is the (BAT) Best Available Treatment, for the SLS Phase 3 Control Arm AML CR2 patients - FAILED - 3 Large, Expensive Phase 3 Trials $ABBV was conducting. Including the VIALE-M Maintenance Trial for AML CR1 Patients. - FAILED Aza + VEN is also FAILING the Control Arm AML CR2 Patients in the SLS REGAL Phase 3.
0 · Reply
Luckyjs38
Luckyjs38 Oct. 23 at 2:03 PM
$ABBV $ENVB
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 6:52 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABBV Current Share Price: $228.68 Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $24.55- $30.00 Scale out: $38.18-$49.09 Can Easily Capture: 60% ROI Blended DTE: 450 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
TalkMarkets
TalkMarkets Oct. 23 at 5:37 AM
This 3 Stocks Portfolio Provides Monthly Income $KO $XOM $ABBV https://talkmarkets.com/content/stocks--equities/this-3-stocks-portfolio-provides-monthly-income?post=529893
0 · Reply